FF 
Principal Investigator/Program Director (Last, first, middle): 
BIOGRAPHICAL SKETCH 
Give the following information for the key personnel and consultants and collaborators Begin with the principal 
investigator/program director. Photocopy this page for each person 
CVs 
NAME 
HESLOP, Helen Elisabeth 
POSITION TITLE 
Asst. Member, BMT; Hematology-Oncology 
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training ) 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
U. Otago, Dunedin, New Zealand 
MB ChB 
1980 
Medicine 
Royal Australasian Col. of Physicians 
FRACP 
1987 
Medicine 
Royal Australasian Col. of Pathologists 
FRCPA 
1987 
Hemat/lmmunol 
U. Otago, New Zealand 
MD 
1990 
Hematology 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, experience, and 
honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. 
Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or 
baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on 
any Federal Government public advisory committee. List, in chronological order, the titles, all authors, and complete references to all publications during the 
past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES. 
1980-82 
1982-84 
1984-85 
1986-89 
1989-91 
1991 to 
present 
1991 to 
present 
House Officer/Senior House Officer, Canterbury Hospital Board, Christchurch, 
New Zealand 
Medical Registrar, Canterbury Hospital Board, Christchurch, New Zealand 
Senior Registrar in Hematology, Canterbury Hospital Board, Christchurch, New 
Zealand 
Research Fellow/Honorary Lecturer, Royal Free Hospital, London, England 
Postdoctoral Research Associate, Department of Biochemistry and Hematology- 
Oncology, St. Jude Children's Research Hospital, Memphis, TN 
Assistant Professor, Department of Pediatrics, University of Tennessee, 
Memphis, College 
Medicine, Tennessee 
Assistant Member, Disivison of Bone Marrow Transplantation, Department of 
Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, 
Tennessee 
PUBLICATIONS (From a total of 57) f 
(• 
fi 
Heslop HE, Gottlieb DJ, Bianchi ACM, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, j; 
Brenner MK. In vivo induction of gamma interferon and tumour necrosis factor by 
Interleukin 2 infusion following intensive chemotherapy or autologous marrow ' 
transplantation. Blood 74:1374-1380, 1989. 
Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi ACM, Galazka A, Brenner ij 
MK. Effects of recombinant Interleukin 2 administration on cytotoxic function following 
high dose chemoradiotherapy for hematological malignancy. Blood 74:2335-2342, ’ 
1989. [ 
Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exiey T, Brenner MK. Tumour 
necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol 
143:3828-3834, 1989. ' 
Bianchi ACM, Heslop HE, Veys P, Macey M, Holland M, Prentice HG, Brenner MK. 
Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and f 
GMCSF. Br J Haematol 73:468-474, 1989. , 
[510] 
Recombinant DNA Research, Volume 19 
